Nothing Special   »   [go: up one dir, main page]

GB201804027D0 - Anti-CD25 antibody agents - Google Patents

Anti-CD25 antibody agents

Info

Publication number
GB201804027D0
GB201804027D0 GBGB1804027.9A GB201804027A GB201804027D0 GB 201804027 D0 GB201804027 D0 GB 201804027D0 GB 201804027 A GB201804027 A GB 201804027A GB 201804027 D0 GB201804027 D0 GB 201804027D0
Authority
GB
United Kingdom
Prior art keywords
antibody agents
antibody
agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1804027.9A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cancer Research Technology Ltd
Tusk Therapeutics Ltd
Original Assignee
Cancer Research Technology Ltd
Tusk Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Research Technology Ltd, Tusk Therapeutics Ltd filed Critical Cancer Research Technology Ltd
Priority to GBGB1804027.9A priority Critical patent/GB201804027D0/en
Publication of GB201804027D0 publication Critical patent/GB201804027D0/en
Priority to MX2020008770A priority patent/MX2020008770A/en
Priority to US16/352,703 priority patent/US10738125B2/en
Priority to EP19709955.9A priority patent/EP3765503B1/en
Priority to CN201980019257.2A priority patent/CN112218891B/en
Priority to JP2020547326A priority patent/JP7563978B2/en
Priority to PCT/EP2019/056249 priority patent/WO2019175217A1/en
Priority to BR112020016501-8A priority patent/BR112020016501A2/en
Priority to PCT/EP2019/056248 priority patent/WO2019175216A1/en
Priority to SG11202008784RA priority patent/SG11202008784RA/en
Priority to PE2020001320A priority patent/PE20210289A1/en
Priority to US16/979,933 priority patent/US11919960B2/en
Priority to US16/979,935 priority patent/US11697688B2/en
Priority to US16/979,932 priority patent/US11873341B2/en
Priority to TW108108452A priority patent/TW201940515A/en
Priority to JP2020547399A priority patent/JP7451415B2/en
Priority to KR1020207029221A priority patent/KR20200131861A/en
Priority to SG11202008699WA priority patent/SG11202008699WA/en
Priority to RU2020128108A priority patent/RU2020128108A/en
Priority to CR20200467A priority patent/CR20200467A/en
Priority to PCT/EP2019/056260 priority patent/WO2019175226A1/en
Priority to EP19709957.5A priority patent/EP3765505B1/en
Priority to US16/979,930 priority patent/US11814434B2/en
Priority to US16/352,709 priority patent/US10752691B2/en
Priority to EP19709954.2A priority patent/EP3765502B1/en
Priority to EP19709958.3A priority patent/EP3765506B1/en
Priority to EP19711315.2A priority patent/EP3765511B1/en
Priority to US16/979,931 priority patent/US11851494B2/en
Priority to JP2020547332A priority patent/JP7565797B2/en
Priority to EP19710416.9A priority patent/EP3765507B1/en
Priority to CA3088671A priority patent/CA3088671A1/en
Priority to TW108108467A priority patent/TW202003034A/en
Priority to TW108108451A priority patent/TW201938588A/en
Priority to CN201980019234.1A priority patent/CN112074536B/en
Priority to SG11202008733YA priority patent/SG11202008733YA/en
Priority to MX2020008769A priority patent/MX2020008769A/en
Priority to CN201980019247.9A priority patent/CN112020513B/en
Priority to US16/352,717 priority patent/US10745485B2/en
Priority to MA051993A priority patent/MA51993A/en
Priority to US16/979,929 priority patent/US11802161B2/en
Priority to KR1020207029229A priority patent/KR20200131862A/en
Priority to PCT/EP2019/056257 priority patent/WO2019175223A1/en
Priority to CA3088659A priority patent/CA3088659A1/en
Priority to KR1020207029205A priority patent/KR20200131286A/en
Priority to PE2020001292A priority patent/PE20210287A1/en
Priority to AU2019233576A priority patent/AU2019233576A1/en
Priority to JP2020547371A priority patent/JP7474701B2/en
Priority to BR112020016499-2A priority patent/BR112020016499A2/en
Priority to JP2020547415A priority patent/JP2021515568A/en
Priority to JP2020547333A priority patent/JP7510348B2/en
Priority to CN201980019256.8A priority patent/CN112020516A/en
Priority to JP2020547331A priority patent/JP7563979B2/en
Priority to CR20200465A priority patent/CR20200465A/en
Priority to AU2019233575A priority patent/AU2019233575A1/en
Priority to CA3088246A priority patent/CA3088246A1/en
Priority to BR112020016519-0A priority patent/BR112020016519A2/en
Priority to PCT/EP2019/056256 priority patent/WO2019175222A1/en
Priority to MX2020008768A priority patent/MX2020008768A/en
Priority to PE2020001299A priority patent/PE20210288A1/en
Priority to AU2019233581A priority patent/AU2019233581A1/en
Priority to PCT/EP2019/056258 priority patent/WO2019175224A1/en
Priority to CN201980019248.3A priority patent/CN112020514B/en
Priority to CN201980019235.6A priority patent/CN112041345A/en
Priority to EP19711075.2A priority patent/EP3765510A1/en
Priority to PCT/EP2019/056247 priority patent/WO2019175215A1/en
Priority to JP2020547363A priority patent/JP7451414B2/en
Priority to CN201980019241.1A priority patent/CN112020512A/en
Priority to CR20200466A priority patent/CR20200466A/en
Priority to RU2020128081A priority patent/RU2020128081A/en
Priority to CN201980019249.8A priority patent/CN112020515B/en
Priority to PCT/EP2019/056252 priority patent/WO2019175220A1/en
Priority to MA051997A priority patent/MA51997A/en
Priority to MA051992A priority patent/MA51992A/en
Priority to EP19709956.7A priority patent/EP3765504B1/en
Priority to US16/782,461 priority patent/US11787866B2/en
Priority to US16/782,440 priority patent/US11802160B2/en
Priority to CONC2020/0009476A priority patent/CO2020009476A2/en
Priority to ZA2020/04771A priority patent/ZA202004771B/en
Priority to CONC2020/0009758A priority patent/CO2020009758A2/en
Priority to CONC2020/0009743A priority patent/CO2020009743A2/en
Priority to IL276995A priority patent/IL276995A/en
Priority to IL276992A priority patent/IL276992A/en
Priority to IL276997A priority patent/IL276997A/en
Priority to CL2020002339A priority patent/CL2020002339A1/en
Priority to CL2020002338A priority patent/CL2020002338A1/en
Priority to CL2020002340A priority patent/CL2020002340A1/en
Priority to PH12020551454A priority patent/PH12020551454A1/en
Priority to PH12020551451A priority patent/PH12020551451A1/en
Priority to PH12020551453A priority patent/PH12020551453A1/en
Priority to CL2021002603A priority patent/CL2021002603A1/en
Priority to US18/470,875 priority patent/US20240309101A1/en
Ceased legal-status Critical Current

Links

GBGB1804027.9A 2018-03-13 2018-03-13 Anti-CD25 antibody agents Ceased GB201804027D0 (en)

Priority Applications (91)

Application Number Priority Date Filing Date Title
GBGB1804027.9A GB201804027D0 (en) 2018-03-13 2018-03-13 Anti-CD25 antibody agents
MX2020008770A MX2020008770A (en) 2018-03-13 2019-03-13 Anti-cd25 for tumour specific cell depletion.
US16/352,703 US10738125B2 (en) 2018-03-13 2019-03-13 Anti-CD25 antibody agents
EP19709955.9A EP3765503B1 (en) 2018-03-13 2019-03-13 Anti-cd25 for tumour specific cell depletion
CN201980019257.2A CN112218891B (en) 2018-03-13 2019-03-13 Anti-CD 25 antibody agents
JP2020547326A JP7563978B2 (en) 2018-03-13 2019-03-13 Anti-CD25 for tumor-specific cell depletion
PCT/EP2019/056249 WO2019175217A1 (en) 2018-03-13 2019-03-13 Anti-cd25 for tumour specific cell depletion
BR112020016501-8A BR112020016501A2 (en) 2018-03-13 2019-03-13 antibody or antigen-binding fragment thereof, antibody or an antigen-binding fragment that specifically bind to a human cd25 epotype, affinity-matured variant of an antibody or its antigen-binding fragment, nucleic acid molecule, vector nucleic acid, host cell, method for producing an antibody or antigen-binding fragment thereof, pharmaceutical composition, use of an antibody or antigen-binding fragment thereof, method for treating cancer in an individual, method for depleting t cells regulators in a tumor in an individual, antibody or antigen-binding fragment that competes with an antibody, kit, method for preparing an anti-cd25 antibody and method for preparing a pharmaceutical composition
PCT/EP2019/056248 WO2019175216A1 (en) 2018-03-13 2019-03-13 Anti-cd25 for tumour specific cell depletion
SG11202008784RA SG11202008784RA (en) 2018-03-13 2019-03-13 Anti-cd25 for tumour specific cell depletion
PE2020001320A PE20210289A1 (en) 2018-03-13 2019-03-13 ANTI-CD25 FOR THE DEPLETION OF SPECIFIC TUMOR CELLS
US16/979,933 US11919960B2 (en) 2018-03-13 2019-03-13 Anti-CD25 antibody agents
US16/979,935 US11697688B2 (en) 2018-03-13 2019-03-13 Anti-CD25 for tumour specific cell depletion
US16/979,932 US11873341B2 (en) 2018-03-13 2019-03-13 Anti-CD25 for tumour specific cell depletion
TW108108452A TW201940515A (en) 2018-03-13 2019-03-13 Anti-CD25 antibody agents
JP2020547399A JP7451415B2 (en) 2018-03-13 2019-03-13 Anti-CD25 for tumor-specific cell depletion
KR1020207029221A KR20200131861A (en) 2018-03-13 2019-03-13 Anti-CD25 against tumor specific cell depletion
SG11202008699WA SG11202008699WA (en) 2018-03-13 2019-03-13 Anti-cd25 for tumour specific cell depletion
RU2020128108A RU2020128108A (en) 2018-03-13 2019-03-13 ANTIBODY AGAINST CD25 FOR TUMOR-SPECIFIC CELL DEPLETION
CR20200467A CR20200467A (en) 2018-03-13 2019-03-13 Anti-cd25 for tumour specific cell depletion
PCT/EP2019/056260 WO2019175226A1 (en) 2018-03-13 2019-03-13 Anti-cd25 antibody agents
EP19709957.5A EP3765505B1 (en) 2018-03-13 2019-03-13 Anti-cd25 for tumour specific cell depletion
US16/979,930 US11814434B2 (en) 2018-03-13 2019-03-13 Anti-CD25 for tumour specific cell depletion
US16/352,709 US10752691B2 (en) 2018-03-13 2019-03-13 Anti-CD25 antibody agents
EP19709954.2A EP3765502B1 (en) 2018-03-13 2019-03-13 Anti-cd25 for tumour specific cell depletion
EP19709958.3A EP3765506B1 (en) 2018-03-13 2019-03-13 Anti-cd25 for tumour specific cell depletion
EP19711315.2A EP3765511B1 (en) 2018-03-13 2019-03-13 Anti-cd25 for tumour specific cell depletion
US16/979,931 US11851494B2 (en) 2018-03-13 2019-03-13 Anti-CD25 for tumour specific cell depletion
JP2020547332A JP7565797B2 (en) 2018-03-13 2019-03-13 Anti-CD25 for tumor-specific cell depletion
EP19710416.9A EP3765507B1 (en) 2018-03-13 2019-03-13 Anti-cd25 antibody agents
CA3088671A CA3088671A1 (en) 2018-03-13 2019-03-13 Anti-cd25 for tumour specific cell depletion
TW108108467A TW202003034A (en) 2018-03-13 2019-03-13 Anti-CD25 antibody agents
TW108108451A TW201938588A (en) 2018-03-13 2019-03-13 Anti-CD25 antibody agents
CN201980019234.1A CN112074536B (en) 2018-03-13 2019-03-13 Anti-CD 25 for tumor specific cell clearance
SG11202008733YA SG11202008733YA (en) 2018-03-13 2019-03-13 Anti-cd25 for tumour specific cell depletion
MX2020008769A MX2020008769A (en) 2018-03-13 2019-03-13 Anti-cd25 for tumour specific cell depletion.
CN201980019247.9A CN112020513B (en) 2018-03-13 2019-03-13 Anti-CD 25 for tumor specific cell clearance
US16/352,717 US10745485B2 (en) 2018-03-13 2019-03-13 Anti-CD25 antibody agents
MA051993A MA51993A (en) 2018-03-13 2019-03-13 ANTI-CD25 ANTIBODIES FOR TUMOR-SPECIFIC CELL DELETION
US16/979,929 US11802161B2 (en) 2018-03-13 2019-03-13 Anti-CD25 for tumour specific cell depletion
KR1020207029229A KR20200131862A (en) 2018-03-13 2019-03-13 Anti-CD25 against tumor specific cell depletion
PCT/EP2019/056257 WO2019175223A1 (en) 2018-03-13 2019-03-13 Anti-cd25 for tumour specific cell depletion
CA3088659A CA3088659A1 (en) 2018-03-13 2019-03-13 Anti-cd25 for tumour specific cell depletion
KR1020207029205A KR20200131286A (en) 2018-03-13 2019-03-13 Anti-CD25 against tumor specific cell depletion
PE2020001292A PE20210287A1 (en) 2018-03-13 2019-03-13 ANTI-CD25 FOR THE DEPLETION OF SPECIFIC TUMOR CELLS
AU2019233576A AU2019233576A1 (en) 2018-03-13 2019-03-13 Anti-CD25 for tumour specific cell depletion
JP2020547371A JP7474701B2 (en) 2018-03-13 2019-03-13 Anti-CD25 antibodies for tumor-specific cell depletion
BR112020016499-2A BR112020016499A2 (en) 2018-03-13 2019-03-13 antibody or antigen-binding fragment thereof, antibody or antigen-binding fragment that specifically bind to a human cd25 epotype, affinity-matured variant, nucleic acid molecule and vector, host cell, method for producing an antibody or antigen binding fragment thereof, composition, pharmaceutical composition, use of an antibody or antigen binding fragment thereof, method for treating cancer in an individual, method for depleting regulatory t cells in a tumor in an individual, antibody or fragment antigen-binding compound that competes with an antibody, kit, method for preparing an anti-cd25 antibody and method for preparing a pharmaceutical composition
JP2020547415A JP2021515568A (en) 2018-03-13 2019-03-13 Anti-CD25 for tumor-specific cell depletion
JP2020547333A JP7510348B2 (en) 2018-03-13 2019-03-13 Anti-CD25 for tumor-specific cell depletion
CN201980019256.8A CN112020516A (en) 2018-03-13 2019-03-13 anti-CD 25 for tumor specific cell clearance
JP2020547331A JP7563979B2 (en) 2018-03-13 2019-03-13 Anti-CD25 for tumor-specific cell depletion
CR20200465A CR20200465A (en) 2018-03-13 2019-03-13 Anti-cd25 for tumour specific cell depletion
AU2019233575A AU2019233575A1 (en) 2018-03-13 2019-03-13 Anti-CD25 for tumour specific cell depletion
CA3088246A CA3088246A1 (en) 2018-03-13 2019-03-13 Anti-cd25 for tumour specific cell depletion
BR112020016519-0A BR112020016519A2 (en) 2018-03-13 2019-03-13 ANTIBODY OR ANTIGEN BINDING FRAGMENT OF THE SAME, ANTIBODY OR AN ANTIGEN BINDING FRAGMENT THAT SPECIFICALLY LINKS TO A HUMAN CD25 EPOTYPE, AFFINITY MATERIAL, NUCLEAR, NUCLEAR, NUCLEAR, NUCLEAR, NUCLEAR, NUCLEAR, AN ANTIGEN OR ANTIGEN BINDING FRAGMENT OF THE SAME, PHARMACEUTICAL COMPOSITION, USE OF AN ANTIGEN BINDING ANTIBODY OR FRAGMENT, METHOD OF TREATING CANCER IN AN INDIVIDUAL, METHOD OF EMOTION IN AN EMOTIONAL EMOTION ANTIGEN BINDING FRAGMENT THAT COMPETES WITH AN ANTIBODY, KIT, METHOD FOR PREPARING AN ANTI-CD25 ANTIBODY AND METHOD FOR PREPARING A PHARMACEUTICAL COMPOSITION
PCT/EP2019/056256 WO2019175222A1 (en) 2018-03-13 2019-03-13 Anti-cd25 for tumour specific cell depletion
MX2020008768A MX2020008768A (en) 2018-03-13 2019-03-13 Anti-cd25 for tumour specific cell depletion.
PE2020001299A PE20210288A1 (en) 2018-03-13 2019-03-13 ANTI-CD25 FOR THE DEPLETION OF SPECIFIC TUMOR CELLS
AU2019233581A AU2019233581A1 (en) 2018-03-13 2019-03-13 Anti-CD25 for tumour specific cell depletion
PCT/EP2019/056258 WO2019175224A1 (en) 2018-03-13 2019-03-13 Anti-cd25 for tumour specific cell depletion
CN201980019248.3A CN112020514B (en) 2018-03-13 2019-03-13 Anti-CD 25 for tumor specific cell clearance
CN201980019235.6A CN112041345A (en) 2018-03-13 2019-03-13 anti-CD 25 for tumor specific cell clearance
EP19711075.2A EP3765510A1 (en) 2018-03-13 2019-03-13 Anti-cd25 for tumour specific cell depletion
PCT/EP2019/056247 WO2019175215A1 (en) 2018-03-13 2019-03-13 Anti-cd25 for tumour specific cell depletion
JP2020547363A JP7451414B2 (en) 2018-03-13 2019-03-13 Anti-CD25 antibody agent
CN201980019241.1A CN112020512A (en) 2018-03-13 2019-03-13 anti-CD 25 for tumor specific cell clearance
CR20200466A CR20200466A (en) 2018-03-13 2019-03-13 Anti-cd25 for tumour specific cell depletion
RU2020128081A RU2020128081A (en) 2018-03-13 2019-03-13 ANTIBODY AGAINST CD25 FOR TUMOR-SPECIFIC CELL DEPLETION
CN201980019249.8A CN112020515B (en) 2018-03-13 2019-03-13 Anti-CD 25 for tumor specific cell clearance
PCT/EP2019/056252 WO2019175220A1 (en) 2018-03-13 2019-03-13 Anti-cd25 for tumour specific cell depletion
MA051997A MA51997A (en) 2018-03-13 2019-03-13 ANTI-CD25 ANTIBODIES FOR TUMOR-SPECIFIC CELL DELETION
MA051992A MA51992A (en) 2018-03-13 2019-03-13 ANTI-CD25 ANTIBODIES FOR TUMOR-SPECIFIC CELL DELETION
EP19709956.7A EP3765504B1 (en) 2018-03-13 2019-03-13 Anti-cd25 for tumour specific cell depletion
US16/782,461 US11787866B2 (en) 2018-03-13 2020-02-05 Anti-CD25 antibody agents
US16/782,440 US11802160B2 (en) 2018-03-13 2020-02-05 Anti-CD25 antibody agents
CONC2020/0009476A CO2020009476A2 (en) 2018-03-13 2020-07-29 Anti-cd25 for tumor specific cell depletion
ZA2020/04771A ZA202004771B (en) 2018-03-13 2020-07-31 Anti-cd25 for tumour specific cell depletion
CONC2020/0009758A CO2020009758A2 (en) 2018-03-13 2020-08-06 Anti-cd25 antibody agents
CONC2020/0009743A CO2020009743A2 (en) 2018-03-13 2020-08-06 Anti-cd25 antibody agents
IL276995A IL276995A (en) 2018-03-13 2020-08-30 Anti-cd25 for tumour specific cell depletion
IL276992A IL276992A (en) 2018-03-13 2020-08-30 Anti-cd25 for tumour specific cell depletion
IL276997A IL276997A (en) 2018-03-13 2020-08-30 Anti-cd25 for tumour specific cell depletion
CL2020002339A CL2020002339A1 (en) 2018-03-13 2020-09-10 Anti-cd25 for tumor-specific cell depletion
CL2020002338A CL2020002338A1 (en) 2018-03-13 2020-09-10 Anti-cd25 for tumor-specific cell depletion
CL2020002340A CL2020002340A1 (en) 2018-03-13 2020-09-10 Anti-cd25 for tumor-specific cell depletion
PH12020551454A PH12020551454A1 (en) 2018-03-13 2020-09-11 Anti-cd25 for tumour specific cell depletion
PH12020551451A PH12020551451A1 (en) 2018-03-13 2020-09-11 Anti-cd25 for tumour specific cell depletion
PH12020551453A PH12020551453A1 (en) 2018-03-13 2020-09-11 Anti-cd25 for tumour specific cell depletion
CL2021002603A CL2021002603A1 (en) 2018-03-13 2021-10-05 Anti-cd25 for tumor-specific cell depletion (divisional of application no. 202002340)
US18/470,875 US20240309101A1 (en) 2018-03-13 2023-09-20 Anti-cd25 antibody agents

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1804027.9A GB201804027D0 (en) 2018-03-13 2018-03-13 Anti-CD25 antibody agents

Publications (1)

Publication Number Publication Date
GB201804027D0 true GB201804027D0 (en) 2018-04-25

Family

ID=61972981

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1804027.9A Ceased GB201804027D0 (en) 2018-03-13 2018-03-13 Anti-CD25 antibody agents

Country Status (1)

Country Link
GB (1) GB201804027D0 (en)

Similar Documents

Publication Publication Date Title
EP3765507C0 (en) Anti-cd25 antibody agents
IL279321A (en) Anti-sirpĪ± antibody
SG11202106214YA (en) Novel anti-ccr8 antibody
IL280780A (en) Anti-tigit antibodies
IL280013A (en) Anti-il36r antibodies
IL279352A (en) Il-11ra antibodies
IL278010A (en) Galectin-10 antibodies
IL277030A (en) Antibodies
ZA202101177B (en) Anti-btla antibody
GB202110263D0 (en) Anti-btla antibodies
GB201811368D0 (en) Antibody
IL281976A (en) Anti-fgfr2 antibody formulations
GB201817172D0 (en) Antibody
IL281594A (en) Anti-klrg1 antibodies
ZA202108836B (en) Anti-epha4 antibody
IL283886A (en) Antibody formulations
EP4083211A4 (en) Anti-cdcp1 antibody
GB201806084D0 (en) Antibodies
GB201919062D0 (en) Antibody
GB201804029D0 (en) Anti-CD25 antibody agents
GB201804028D0 (en) Anti-CD25 antibody agents
GB201804027D0 (en) Anti-CD25 antibody agents
GB201813597D0 (en) Antibody
GB201809945D0 (en) Antibody
SG11202105718TA (en) Modified antibodies

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)